-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Corcept Therapeutics, Lowers Price Target to $99

Benzinga·01/02/2026 13:07:13
Listen to the news
Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and lowers the price target from $140 to $99.